drugset / Trial / NCT05583149
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
NaSingle-groupOpen-labelTreatment
Summary
This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce
Timeline
- Start
- 2023-03-01
- Primary completion
- 2024-11-23
- Completion
- 2029-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | — | Oral |
| Subject | Lisocabtagene Maraleucel | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |